Physician profile
Paul E Wise
NPI 1619076056
$23,959.48
in general payments reported to CMS, 2019-2025
14 companies · $4,937 in 2025
The $4,937 reported for 2025 was more than what 88% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2021: $2.59 · 2022: $149 · 2023: $149 · 2024: $18K · 2025: $4,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $1,241 · Travel and Lodging: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,232.50 |
| Food and Beverage | $1,240.76 |
| Travel and Lodging | $954.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $21,295.66 | 2024-2025 | |
| Olympus Corporation of The Americas | $1,188.99 | 2024 | |
| Medtronic, INC. | $343.19 | 2022-2025 | Eea, Signia |
| Allergan, INC. | $261.22 | 2019-2022 | |
| Stryker Corporation | $191.10 | 2019-2025 | 1788 |
| Davol INC. | $178.42 | 2025 | |
| Intuitive Surgical, INC. | $172.21 | 2019-2024 | |
| Abbvie INC. | $148.68 | 2023 | Strattice Reconstructive Tissue Matrix Bps |
| Myriad Genetic Laboratories, INC. | $127.43 | 2024 | Myrisk |
| Boston Scientific Corporation | $20.71 | 2025 | Overstitch Endoscopic Suturing System |
| Conmed Corporation | $20.30 | 2019 | |
| Covidien Lp | $11.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.